Selective Immunosuppressants
- Name
- Selective Immunosuppressants
- Accession Number
- DBCAT002129
- Description
Not Available
- ATC Classification
- Drugs
Drug Drug Description Muromonab A monoclonal anti-CD3 antibody used as immunosuppressive therapy in kidney, heart, and liver transplant patients. Alemtuzumab A monoclonal anti-CD52 antibody used in the treatment of B-cell chronic lymphocytic leukemia and relapsing forms of multiple sclerosis. Alefacept A recombinant fusion protein that binds CD2 and is used treat moderate to severe plaque psoriasis. Efalizumab A monoclonal anti-CD11a antibody used to treat moderate to severe plaque psoriasis. Antithymocyte immunoglobulin (rabbit) A purified form of rabbit anti-thymocyte antibodies used for immunosuppression in patients receiving kidney transplants. Natalizumab A monoclonal anti-integrin antibody used to treat Crohn's disease or multiple sclerosis. Sirolimus An mTOR inhibitor immunosuppressant used to prevent organ transplant rejections, treat lymphangioleiomyomatosis, and treat adults with perivascular epithelioid cell tumors. Mycophenolic acid An immunosuppressant used to prevent organ transplant rejections. Leflunomide A pyrimidine synthesis inhibitor indicated to treat rheumatoid arthritis. Eculizumab A recombinant humanized monoclonal antibody used to reduce the risk of hemolysis in paroxysmal nocturnal hemoglobinuria (PNH) and atypical hemolytic uremic syndrome (aHUS). Abatacept A disease-modifying antirheumatic drug (DMARD) used in the management of rheumatic conditions, such as rheumatoid or psoriatic arthritis, and for the prophylaxis of acute graft-versus-host disease. Everolimus A mammalian target of rapamycin (mTOR) kinase inhibitor used to treat various types of malignancies. Apremilast A non-steroidal medication used for the treatment of inflammatory conditions such as psoriasis and psoriatic arthritis. Abetimus Investigated for use/treatment in kidney disease and systemic lupus erythematosus. Belatacept A selective T-cell costimulation blocker used in the prophylaxis of organ rejection in adult patients receiving a kidney transplant. Fingolimod A sphingosine 1-phosphate receptor modulator used to treat patients with the relapsing-remitting form of multiple sclerosis (MS) and studied to manage lung complications of COVID-19. Belimumab A B-lymphocyte stimulator (BLyS)-specific inhibitor used to treat systemic lupus erythematosus and active lupus nephritis as an add-on therapy. Teriflunomide A pyrimidine synthesis inhibitor with anti-inflammatory and immunomodulatory properties used to treat patients with the relapsing-remitting form of multiple sclerosis. Tofacitinib A Janus kinase (JAK) inhibitor used to treat rheumatic conditions, such as rheumatoid arthritis and ankylosing spondylitis, and ulcerative colitis. Vedolizumab An integrin blocker and anti-inflammatory agent used to manage ulcerative colitis and Crohn's disease in adults. Antilymphocyte immunoglobulin (horse) A primarily IgG immune globulin used to manage allograft rejection in renal transplant patients. Gusperimus Gusperimus has been used in trials studying the treatment of Lupus Nephritis, Wegeners Granulomatosis, and Wegener's Granulomatosis. Begelomab Begelomab is a murine monoclonal antibody against CD26. Cladribine A purine antimetabolite used for the management of relapsing forms of Multiple Sclerosis (MS), used in patients who have not responded to or who were unable to tolerate alternative MS drugs. Baricitinib A Janus kinase inhibitor used to treat moderate to severe rheumatoid arthritis that has responded poorly to at least one TNF antagonist. Ocrelizumab A CD20 specific monoclonal antibody used to treat relapsing remitting multiple sclerosis. Ozanimod A sphingosine 1-phosphate receptor modulator being studied to treat Multiple Sclerosis (MS) and inflammatory bowel disease (IBD). Emapalumab An interferon gamma blocking antibody used to treat primary hemophagocytic lymphohistiocytosis. Risankizumab An interleukin-23 antagonist used to treat plaque psoriasis, psoriatic arthritis, and Crohn's disease in adults. Ravulizumab A monoclonal antibody used to treat paroxysmal nocturnal hemoglobinuria, atypical hemolytic uremic syndrome, and myasthenia gravis. Siponimod A medication used to treat relapsing multiple sclerosis. Upadacitinib An oral Janus kinase (JAK)1-selective inhibitor used in the treatment of moderate to severe rheumatoid arthritis, active psoriatic arthritis, ankylosing spondylitis, and severe atopic dermatitis, including in patients who did not respond well to other therapies. Imlifidase A cysteine protease that specifically cleaves human IgG antibodies, facilitating kidney transplantation in HLA sensitized patients. Teprotumumab A fully human monoclonal antibody directed against insulin-like growth factor-1 receptor for the treatment of thyroid eye disease. Ofatumumab An anti-CD20 antibody used for the treatment of chronic lymphocytic leukemia (CLL) in selected patients with certain treatment histories and responsiveness to anticancer medications. Peficitinib Peficitinib has been used in trials studying the treatment and basic science of Psoriasis, Pharmacodynamics, Drug Interactions, Colitis, Ulcerative, and RHEUMATOID ARTHRITIS, among others. Anifrolumab A monoclonal antibody that inhibits type 1 interferon receptors, indicated in the treatment of moderate to severe systemic lupus erythematosus. Ponesimod A sphingosine 1-phosphate receptor modulator indicated to treat relapsing multiple sclerosis. Itacitinib Itacitinib has been used in trials studying the treatment of Melanoma, Carcinoma, Metastatic Cancer, Endometrial Cancer, and B-cell Malignancies, among others. Inebilizumab A humanized anti-CD19 cytolytic monoclonal antibody for B-cell depletion in autoimmune conditions. Currently approved only for neuromyelitis optica spectrum disorder (NMOSD). Filgotinib A Janus kinase (JAK) 1 selective inhibitor used to treat cases of rheumatoid arthritis that are unresponsive to conventional treatments. Sutimlimab A monoclonal antibody directed towards complement subunit C1s used to reduce the need for blood transfusion due to hemolysis in patients with cold agglutinin disease. Deucravacitinib A TYK2 inhibitor being investigated as a treatment for psoriasis. Pegcetacoplan A complement inhibitor indicated in the treatment of adults with paroxysmal nocturnal hemoglobinuria. Belumosudil An oral inhibitor of rho-associated coiled-coil-containing protein kinases (ROCK) used in the treatment of chronic graft-versus-host disease (GVHD). Ublituximab A low-fucose CD20-targeted monoclonal antibody used in the treatment of relapsing forms of multiple sclerosis. Avacopan An orally bioavailable complement 5a receptor (C5aR) antagonist for the treatment of severe anti-neutrophil cytoplasmic (auto)antibody (ANCA)-associated vasculitis. Efgartigimod alfa A neonatal Fc receptor blocker used to treat generalized myasthenia gravis in patients who are AChR-antibody positive. - Drugs & Drug Targets